Injecto Polymers IPO Day 4: GMP ₹0
Alright folks, it’s Day 4 of the Injecto Polymers SME IPO on the BSE, and we’re diving deep into the subscription numbers and Grey Market Premium (GMP). As of today, the subscription figures are still showing a notable lack of activity across all categories. This is a crucial point for any investor considering this offering, and we’ll break down what it all means.
Subscription Status
Let’s get straight to the numbers. For Injecto Polymers, as of Day 4, the subscription is showing 0x for Retail, 0x for NII (Non-Institutional Investors), and 0x for QIB (Qualified Institutional Buyers). This brings the total subscription to a flat 0x. Now, what does this tell us? Typically, by Day 4 of an IPO, especially a retail-focused SME offering, you’d expect to see some traction. The absence of any subscription, even from retail investors, is quite unusual. It could indicate a few things. Perhaps potential investors are waiting for the final day to make their decisions, or they might be holding back due to other market events or a lack of strong conviction in this particular IPO. For NII and QIB categories, zero subscription is a clear signal that these larger players haven’t shown any interest yet. This is something that could concern investors looking for validation from institutional money.
| Category | Subscription | Progress |
|---|---|---|
| Retail | 0.00x | |
| NII / HNI | 0.00x | |
| QIB | 1.57x | |
| Total | 1.57x |
GMP Update
Now, let’s talk about the Grey Market Premium, or GMP. For Injecto Polymers, the current GMP is ₹0. Yesterday, it was also ₹0, meaning there’s been no change. The issue price is set at ₹100, and with a GMP of ₹0, the expected listing price is also around ₹100. A GMP of ₹0 suggests that the market, in the grey market at least, isn’t anticipating any significant listing gains. It’s essentially trading at par with the issue price. This is a stark contrast to IPOs that see strong demand, where the GMP often reflects a healthy premium. The unchanged GMP from yesterday reinforces the current sentiment of a flat market for this IPO. Investors typically look for a positive GMP as an indicator of potential listing day performance. The absence of it here, coupled with the subscription numbers, paints a cautious picture.
Should You Apply?
So, the big question: should you be applying for the Injecto Polymers IPO? Based on the data from Day 4, it’s a tough call. We’re seeing absolutely no subscription across the board, and the GMP is sitting at zero, suggesting no immediate listing gains are expected. The IPO period runs until September 16, 2026, so there’s still a little time left. However, the lack of investor interest so far is a significant red flag. It’s always wise to remember that SEBI’s investor advisory is to invest in IPOs based on your own research and risk appetite, and not solely on GMP. While some investors might see the lack of subscription as an opportunity to get in at the issue price with potential upside, others will view it as a sign of weak fundamentals or market sentiment. The lot size is 1200 shares, so a single lot requires a significant investment. The bottom line is, proceed with extreme caution. Do your homework on Injecto Polymers’ business, financials, and future prospects. Don’t rely solely on the subscription numbers or the GMP. For more detailed information and analysis, you can always View Full Injecto Polymers IPO Details.